Marginum's mission is to revolutionize cancer surgery by providing surgeons with real-time, accurate information about tumor tissues. With the global cancer incidence expected to rise by 55% by 2040, the need for improved surgical tools is more critical than ever. Marginum's innovative technology empowers surgeons to make informed decisions, reducing the need for reoperations and minimizing adverse effects. Marginum is part of the North Karelia Fund managed by Redstone.